The Overall Survival and Safety of Men with Metastatic Hormone-Sensitive Prostate Cancer Treated with Combination Therapy of Novel Androgen Receptor Antagonists and Androgen-Deprivation Therapy: A Systematic Review and Meta-Analysis
Table 1
Search strategies for each database.
Search number
Queries
Queries in pubmed
#1
Search “metastatic prostate cancer” (mesh)
#2
Search ((metastatic prostate cancer (title/abstract)) or metastatic pancreatic cancer (title/abstract))
#3
#1 or #2
#4
Search (((((androgen-deprivation therapy (title/abstract)) or abiraterone (title/abstract)) or enzalutamide (title/abstract)) or apalutamide (title/abstract)) or darolutamide (title/abstract))
#5
#3 and #4
Queries in cochrane
#1
MeSH descriptor: (metastatic prostate cancer) explode all trees
#2
((Metastatic prostate cancer) or (metastatic pancreatic cancer)): Ti, ab, kw
#3
#1 or #2
#4
MeSH descriptor: (androgen-deprivation therapy) explode all trees
#5
((Androgen-deprivation therapy) or (abiraterone) or (enzalutamide) or (apalutamide) or (darolutamide)): Ti, ab, kw
#6
#4 or #5
#7
#3 and #6
Queries in embase
#1
‘Metastatic prostate cancer’/exp or ‘metastatic pancreatic cancer’: Ti, ab
#2
‘Androgen-deprivation therapy’: Ti, ab or ‘abiraterone’: ti, ab or ‘enzalutamide’: Ti, ab or ‘apalutamide’: Ti, ab or ‘darolutamide’: Ti, ab
#3
#1 and #2
Queries in WOS
#1
TS = (metastatic prostate cancer or metastatic pancreatic cancer)
#2
TI = (androgen-deprivation therapy or abiraterone or enzalutamide or apalutamide or darolutamide)
